ELAHERE® Demonstrates 35% Reduction in the Risk of Disease Progression or Death Versus Chemotherapy in FRα-Positive Platinum-Resistant Ovarian Cancer

Results from MIRASOL Also Show ELAHERE is the First Treatment to Demonstrate an Overall Survival Benefit in a Phase 3 Trial in Platinum-Resistant Ovarian Cancer Compared to Chemotherapy


Clinically... | June 4, 2023

Related Keywords

Texas ,United States ,University Of Oklahoma ,Oklahoma ,Chicago ,Illinois ,American ,David Omalley ,Kathleen Moore ,Pivekimab Sunirine ,Mirvetuximab Soravtansine ,Sarah Cannon Phasei Program ,James Cancer Center ,University Of Texas Md Anderson Cancer Center ,American Society Of Clinical Oncology ,Immunogen Inc ,Clinical Research ,Ohio State University ,Department Of Leukemia ,Nasdaq ,Clinical Oncology ,Annual Meeting ,Associate Director ,Gynecologic Oncology ,Initial Report ,Advanced High Grade Epithelial Ovarian ,Primary Peritoneal ,Fallopian Tube Cancers ,High Folate Receptor Alpha Expression ,Late Breaking Abstract Session ,Platinum Sensitive Ovarian ,Fallopian Tube ,Primary Peritoneal Cancer ,Davido Malley ,Positive Acute Myeloid Leukemia ,Naval Daver ,Associate Professor ,Immunogen ,Nc Stock Exchange ,News ,Information ,Press Release ,Results ,Rom ,Mirasol ,Also ,Show ,Tlahere ,Us ,The ,First ,Treatment ,O ,Emonstrate ,N ,Verall ,Survival ,Benefit ,Hase , ,Trial ,Ovarian ,Dancer ,Ompared ,O Imgn Us45253h1014 ,